A296160 Stock Overview
Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Progen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,020.00 |
| 52 Week High | ₩9,380.00 |
| 52 Week Low | ₩2,465.00 |
| Beta | 0 |
| 1 Month Change | -4.75% |
| 3 Month Change | -25.03% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 50.12% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| A296160 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | 0.7% | 0.5% | 0.8% |
| 1Y | n/a | -1.2% | 6.3% |
Return vs Industry: Insufficient data to determine how A296160 performed against the KR Life Sciences industry.
Return vs Market: Insufficient data to determine how A296160 performed against the KR Market.
Price Volatility
| A296160 volatility | |
|---|---|
| A296160 Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A296160's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A296160's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | n/a | www.progen.co.kr |
Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes.
Progen Co., Ltd. Fundamentals Summary
| A296160 fundamental statistics | |
|---|---|
| Market cap | ₩69.55b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A296160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A296160 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A296160 perform over the long term?
See historical performance and comparison